# DMX-200

Type: Product

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/dmx-200
Canonical HTML page: https://getbiobrief.com/entity/dmx-200

## Timeline

- **2026-06-16**: Exclusive License Agreement — Dimerix announces licensing deal with Everest Medicines for Asian commercialization.
- **2026-06**: Eighth DSMB Safety Review — Independent committee finds no safety concerns in ongoing trial.
- **2026-04**: Statistical Power Confirmation — External blinded review confirms the trial retains over 90% statistical power for the primary endpoint.
- **2024-02**: Positive Interim Results — Dimerix reports DMX-200 performing better than placebo in reducing proteinuria in the ACTION3 adult cohort.

## Recent coverage (1 stories)

### Dimerix Taps Everest for DMX-200 Asia License, Phase 3 Trial Enrolls 333 with >90% Power
2026-07-12 17:30:47 · Sentiment: Positive · Impact: 6/10 · Sources: 4

Biotech Dimerix secures a regional licensing deal with Everest Medicines, retaining Western rights for its Phase 3 FSGS candidate. Trial remains on track with strong interim efficacy and clean safety, plus a high probability of success.
Full story: https://getbiobrief.com/story/dimerix-dmx-200-license-everest-biotech

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.